Start-Up Previews, April 2014
This Month's Profile Group, Antibodies Evolve, features profiles of GamaMabs, Numab, and Zebra Biologics. Plus these Start-Ups Across Health Care: CoolCore Biomedical Technologies, EBS Technologies, and Xeltis.
You may also be interested in...
EBS Technologies GMBH is shattering the current paradigm that once a person loses sight it cannot be regained. Its NEXT WAVE repetitive retinofugal alternate current stimulation technology uses noninvasive electrical stimulation to reactivate networks of “silent neurons” in patients with ophthalmic diseases or who have lost vision following brain injury.
Rather than relying on an animal or cadaver implant to repair severe congenital heart malformations, Xeltis AG has developed a synthetic and biodegradable replacement pulmonary valve, designed to stimulate and guide the body’s natural healing response. The company’s technology, which has opened up an entirely new therapeutic category called endogenous tissue growth, is designed to provide a single intervention that can last for a lifetime.
Similar to holding a lighted match near a thermostat to induce a lower room temperature, CoolCore Biomedical Technologies LLC’s technology cools the body by tricking it into thinking it is hotter than it actually is. According to its founders, SmartCool is the only totally noninvasive effective cooling technology designed to prevent or limit reperfusion injury (brain and tissue damage) within the critical initial time frame following an ischemic event such as sudden cardiac arrest, stroke, or traumatic brain injury.